

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Jaap Van Der Louw, Dirk Leysen, Roberta Buma Bursi

Examiner: S. Oazi

Application No.: 09/937,274

Group Art Unit 1616

Filing Date: 09/24/2001

For: orally active 7.alpha.-alkyl androgens

Attorney: Mark W. Milstead

Registration Number 45,825 AKZO Nobel Patent Department

405 State Street

Millsboro DE 19966 USA

DECLARATION UNDER 37 C.F.R. 1.132

I, Marcel E. De Gooijer, declare as follows:


I am a pharmacologist, presently employed by N.V. Organon in the Netherlands as senior scientist in the pharmacology department.

I am, as member of a lead optimisation team, involved in pre-clinical research to find new androgenic compounds for medical use.

I am familiar with the contents of the patent application for which this declaration is submitted to the US Patent Office and I am familiar with the publication of Solo et al., Steroids, 40 (6), 1982, 603-614.

I declare that the information, which is provided in the following paragraphs of this declaration is a truthful description of results of experiments performed in the laboratories of Organon and filed as such in our archives.

In an in vitro assay androgenic activity of compounds was measured with Chinese hamster ovary (CHO) cells transfected with the human androgen receptor in combination with a mouse mammary tumor virus, and luciferase 2



The $t_{1/2}$ of a compound after incubation with human hepatocytes was determined in hepatocytes collected from healthy young (25-45 year) male organ donors. The hepatocytes were cryo preserved in liquid nitrogen and kept there until use. These were thawed at 37 °C in a waterbath, placed immediately on ice, washed twice in one volume of cold (4 °C) incubation medium [William's medium E (without phenol red) with Glutamax I®, gentamicin 50 \Box g/ml, insulin 1 \Box M, hydrocortisone hemisuccinate 10 \Box M, fetal calf serum 0 % (v/v)], counted and the viability checked by Trypan blue exclusion. Cells were incubated as suspensions in 12-wells (non-coated) plates at a nominal density of 0.5 x 10° cells/well in 1.5 ml medium at 37 °C with an air/O₂/CO₂ mixture (55/40/5). The plates were set on an orbital shaker at approximately 10 rpm.

The hepatocytes were incubated with 10 nM final concentration of the compound to be tested. The incubations were stopped after 0.5, 1 and 3 h by pipetting the whole incubation mixture into a glass tube and adding one volume of acetone on ice. The acetone was dried under a nitrogen flow at room temperature, the volume adjusted to 1.5 ml and the tubes were centrifuged at $4 \, ^{\circ}$ C at $10.000 \times g$ for 30 min. The de-proteinized supernatants were collected for LC-MS/MS analysis.

The following results were obtained with these methods:

Table of results

A: Androgen receptor activity

B: Metabolic stability t1/2 (min) with human hepatocytes

Compound structure	Compound name	Measurement results	
		A	В
CH ³ OH	7α-methyl- testosterone	45%	
сн3 он	testosterone	16.5%	15 min

3

Compound structure Compound name A B Nandrolone (19- nortestosterone Nandrolone (19- nortestosterone Nandrolone (19- nortestosterone Nandrolone (19- nortestosterone 152% 48 min 152% 48 min 152% 48 min 152% 48 min 76-rethyl- nandrolone (17α- cthyl, 17β- hydroxy estr-4- en-3-one) 14% ethyl nandrolone (17α-ethyl-17α- ethyl nandrolone (17α-ethyl-17β- hydroxy-7β- methyl-estr-4- en-3-one) 7α-methyl nandrolone; MENT; 7α- methyl-19- nortestosterone 7β-methyl nandrolone 14% 7β-methyl nandrolone 14% 14% 14% 14% 14% 14% 14% 14	Table continued			<u>:</u>
Nandrolone (19- nortestosterone Nandrolone (19- nortestosterone 7α-ethyl- nandrolone (7α- ethyl, 17β- hydroxy estr-4- en-3-one) CH ₃ OH Tβ-methyl-17α- ethyl nandrolone (17α-ethyl-17β- hydroxy-7β- methyl-estr-4- en-3-one) CH ₃ OH Nandrolone (19- 55% 48 min 7β-methyl-17α- ethyl nandrolone (17α-ethyl-17α- ethyl nandrolone (17α-ethyl-17β- hydroxy-7β- methyl-19- nortestosterone CH ₃ OH Tβ-methyl nandrolone CH ₃ OH Tβ-methyl nandrolone 14% 20 min 14% 14% 14% 14% 14% 14% 14% 14	Compound structure	Compound name	M asurement r sults	
nortestosterone CH ₃ OH H CH ₃ CH ₄ Tβ-methyl-17α- ethyl androlone (17α-ethyl-17β- hydroxy-7β- methyl-estr-4- en-3-one) CH ₃ OH Tα-methyl nandrolone; MENT; 7α- methyl-19- nortestosterone Tβ-methyl nandrolone CH ₃ OH Tβ-methyl nandrolone Tβ-methyl nandrolone 14% Tβ-winyl nandrolone 190% 21 min Tβ-vinyl nandrolone Namin 152% 48 min 16 min 16 min 16 min 16 min 16 min 16 min 170- 18 min 18 min 18 min 190% 190% 20 min 190% 21 min 190% 21 min 190% 190% 21 min 190%			A	В
CH ₃ OH CH ₃ CH ₃ CH CH ₃ CH ₃ CH Tα-methyl nandrolone; MENT; 7α- methyl-19- nortestosterone CH ₃ CH CH ₃ CH Tβ-methyl nandrolone MENT; 7α- methyl-19- nortestosterone CH ₃ CH Tβ-methyl nandrolone SBW 190% 21 min 7β-vinyl nandrolone	снон	Nandrolone (19-	55%	16 min
CH ₃ OH H CH ₃ CH ₃ CH ₃ -CH ₃ CH ₃ -CH ₃ CH ₃ OH R Tβ-methyl-17α- ethyl nandrolone (17α-ethyl-17β- hydroxy-7β- methyl-estr-4- en-3-one) CH ₃ OH 7α-methyl nandrolone; MENT; 7α- methyl-19- nortestosterone CH ₃ OH Tβ-methyl nandrolone CH ₃ OH Tα-methyl nandrolone Tβ-methyl nandrolone CH ₃ OH Tβ-methyl nandrolone SR Tβ-methyl nandrolone CH ₃ OH Tβ-methyl nandrolone SR Tβ-methyl nandrolone SR Tβ-methyl nandrolone CH ₃ OH Tβ-methyl nandrolone SR Tβ-methyl nandrolone	l i	nortestosterone		
CH ₃ OH H CH ₃ CH ₃ CH ₃ -CH ₃ CH ₃ -CH ₃ CH ₃ OH R Tβ-methyl-17α- ethyl nandrolone (17α-ethyl-17β- hydroxy-7β- methyl-estr-4- en-3-one) CH ₃ OH 7α-methyl nandrolone; MENT; 7α- methyl-19- nortestosterone CH ₃ OH Tβ-methyl nandrolone CH ₃ OH Tα-methyl nandrolone Tβ-methyl nandrolone CH ₃ OH Tβ-methyl nandrolone SR Tβ-methyl nandrolone CH ₃ OH Tβ-methyl nandrolone SR Tβ-methyl nandrolone SR Tβ-methyl nandrolone CH ₃ OH Tβ-methyl nandrolone SR Tβ-methyl nandrolone				
nandrolone (7α- cthyl, 17β- hydroxy estr-4- en-3-one) 7β-methyl-17α- ethyl nandrolone (17α-ethyl-17β- hydroxy-7β- methyl-estr-4- en-3-one) 7α-methyl nandrolone; MENT; 7α- methyl-19- nortestosterone 7β-methyl nandrolone 8% 7α-vinyl nandrolone				
cthyl, 17β- hydroxy estr-4- en-3-one) 7β-methyl-17α- ethyl nandrolone (17α-ethyl-17β- hydroxy-7β- methyl-estr-4- en-3-one) CH ₃ OH 7α-methyl nandrolone; MENT; 7α- methyl-19- nortestosterone CH ₃ OH 7β-methyl nandrolone 14% 7β-methyl nandrolone 14% 7β-methyl 190% 21 min 7β-vinyl nandrolone 8% 7β-vinyl nandrolone	CH² OH	7α-ethyl-	152% /	48 min
hydroxy estr-4- en-3-one) 7β-methyl-17α- ethyl nandrolone (17α-ethyl-17β- hydroxy-7β- methyl-estr-4- en-3-one) CH ₃ OH 7α-methyl nandrolone; MENT; 7α- methyl-19- nortestosterone CH ₃ OH 7β-methyl nandrolone 14% 269% 20 min 7β-methyl nandrolone 14% 7β-methyl 190% 21 min 7β-vinyl nandrolone	H	nandrolone (7α- \		
CH ₃ -CH ₃ Tβ-methyl-17α- ethyl nandrolone (17α-ethyl-17β- hydroxy-7β- methyl-estr-4- en-3-one) 7α-methyl nandrolone; MENT; 7α- methyl-19- nortestosterone CH ₃ OH Tβ-methyl 14% Tβ-methyl 14% 14% 14% 14% 14% 14% 14% 14%		ethyl, 17β-		ł
CH ₃ OH Tα-methyl nandrolone; MENT; τα- methyl-19- nortestosterone CH ₃ OH Tβ-methyl 14% 269% 20 min nandrolone; MENT; τα- methyl-19- nortestosterone Tβ-methyl 14% 14% 14% 14% 14% 14% 14% 14		hydroxy estr-4-		1
ethyl nandrolone (17α-ethyl-17β- hydroxy-7β- methyl-estr-4- en-3-one) CH ₃ OH NENT; 7α- methyl-19- nortestosterone CH ₃ OH Tβ-methyl nandrolone CH ₃ OH Tβ-methyl nandrolone 14% Tβ-methyl nandrolone 190% 21 min Tβ-vinyl nandrolone Tβ-vinyl nandrolone NENT: Refrech; Refrech	CH ₂ -CH ₃	en-3-one)		
cH ₃ -CH ₃ -CH ₃ cH ₃ -CH ₃ cH ₃ -CH ₃ hydroxy-7β- methyl-estr-4- en-3-one) CH ₃ OH nandrolone; MENT; 7α- methyl-19- nortestosterone CH ₃ OH randrolone Remain and rolone 14% randrolone 190% 21 min randrolone Remain and rolone Rem	CH ² OH		14%	
CH ₃ (17α-ethyl-17β-hydroxy-7β-methyl-estr-4-en-3-one) CH ₃ OH CH ₃ OH CH ₃ OH Tα-methyl nandrolone; MENT; 7α-methyl-19-nortestosterone CH ₂ OH Tβ-methyl nandrolone 14% Tα-vinyl nandrolone 190% 21 min 7β-vinyl nandrolone 8%	H CH2-CH3	_ ·		
hydroxy-7β-methyl-estr-4-en-3-one) CH ₃ OH Tα-methyl nandrolone; MENT; 7α- methyl-19- nortestosterone CH ₃ OH Tβ-methyl nandrolone 14% Tα-vinyl nandrolone 190% 21 min nandrolone 7β-vinyl nandrolone 8%		-		
methyl-estr-4- en-3-one) CH ₃ OH 7α-methyl nandrolone; MENT; 7α- methyl-19- nortestosterone CH ₃ OH 7β-methyl nandrolone CH ₃ OH 7α-vinyl nandrolone 190% 21 min 7α-vinyl nandrolone 7β-vinyl nandrolone 7β-vinyl nandrolone		· ·		{
en-3-one) 7α-methyl nandrolone; MENT; 7α- methyl-19- nortestosterone CH ₃ OH nandrolone 7β-methyl nandrolone 14% 7α-vinyl nandrolone 190% 21 min 7β-vinyl nandrolone 8%	Q. CH			<u> </u>
CH ₃ OH Rentryl 19- nortestosterone CH ₃ OH Tβ-methyl nandrolone CH ₃ OH Tβ-methyl nandrolone CH ₃ OH Tβ-methyl nandrolone 14% 190% 21 min 7β-vinyl nandrolone 7β-vinyl nandrolone 7β-vinyl nandrolone		i -	/ \	
nandrolone; MENT; 7α- methyl-19- nortestosterone CH ₃ OH Tβ-methyl nandrolone 14% 7α-vinyl nandrolone CH ₃ OH Tα-vinyl nandrolone 7β-vinyl nandrolone 8%	CH ² OH		269%	20 min
MENT; 7α- methyl-19- nortestosterone CH ₃ OH R CH ₃ OH Tβ-methyl nandrolone 14% 7α-vinyl nandrolone 190% 21 min 7β-vinyl nandrolone 8%	н	· · ·	\ \ \ \ \ \	1
methyl-19- nortestosterone CH ₃ OH Tβ-methyl nandrolone 14% 7α-vinyl nandrolone 190% 21 min 7β-vinyl nandrolone 7β-vinyl nandrolone			A.	
nortestosterone CH ₃ OH Tβ-methyl nandrolone 14% CH ₃ OH Tα-vinyl nandrolone 190% 21 min 7β-vinyl nandrolone 7β-vinyl nandrolone 8%				
CH ₃ OH CH ₃ OH Tβ-methyl nandrolone 14% 14% 14% 14% 14% 14% 14% 14	CH,		\\\^3 \/\	•
nandrolone CH ₃ OH CH ₃ OH nandrolone 7α-vinyl nandrolone 7β-vinyl nandrolone 8%	снон		7	
CH ₃ OH CH ₃ OH Tα-vinyl nandrolone 7β-vinyl nandrolone 8%	н	_		
CH ₃ OH 7α-vinyl 190% 21 min nandrolone CH ₃ OH 7β-vinyl 8% nandrolone				
CH ₃ OH 7α-vinyl 190% 21 min nandrolone CH ₃ OH 7β-vinyl 8% nandrolone				
nandrolone CH=CH ₂ CH ₃ OH Anandrolone 7β-vinyl nandrolone	- Crz		1	
CH=CH ₂ CH ₃ OH 7β-vinyl nandrolone 8%	CH ³ Au	_	190%	21 min
CH ₃ OH 7β-vinyl 8% nandrolone	# (\	nandrolone		
CH ₃ OH 7β-vinyl 8% nandrolone	$\nearrow \nearrow \nearrow$		_	
CH ₃ OH 7β-vinyl 8% nandrolone	O CH=CH			
nandrolone		78	90/	
	\sim 1.		0%	
о Сн=сн		nandroione		
O CH=CH ₂				
	O CH=CH ₂			

NV DRGANON PAT DEPT.

CKSTONE US

Ø 006

4

From these results I conclude that the comparison of MENT with 7β -methyl nandrolone or 7α -vinyl nandrolone with 7β -vinyl nandrolone, shows the major improvement in androgen receptor activation by selecting the 7α -stereoconfiguration.

Furthermore, although some activity is lost for the 7α-ethyl-nandrolone in the in vitro androgen receptor assay, there is higher activity by oral administration.

The results also show that testosterone analogues have much lower activity than nandrolone analogues. The superior activities of 7α -methyl and 7α -ethyl in the nandrolone series can not be derived from data obtained with testosterone analogues.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment, or both, under 17 U.S.C. 1001 and that such wilful false statements may jeopardise the validity of the application or any patent issued thereon.

Number of pages of this declaration: 4 pages.

2002- NOVEMBER - 26

Date

M. E. De Gooijer